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I congratulate the authors on an interesting, instructive, and timely paper. Certainly, including the testing for
SARS-CoV-2 example in a paper on a topic—group testing—of wide interest during the current COVID-19 pandemic
emphasizes the relevance of the topic in public health and diagnostic medicine generally. But the thoughtful inclusion of
the remaining examples—HIV, HPV, and cancer biomarker detection—illustrates that the issues considered are impor-
tant even in less urgent times. In this note of discussion I will comment on two particular aspects in the paper that
I found particularly informative, and then I will comment on two other, related areas that I believe the conclusions
inform.
I found the direct use of explicit constraints on Se(k) and Sp(k) in design optimization natural and, as the authors
say, “very easy to interpret and explain to non-statisticians.” Incorporating these constraints at the outset of design
optimization should have the further, philosophical advantage that consideration of and specification of these must
(ideally) be made by subject matter experts before cost evaluations are undertaken, so that screening and diagnostic
needs rather than cost constraints do not unduly drive (or result in inadvertant or active manipulation of) performance
requirements.
The authors’ investigation of the use of uncertain values or estimates for Se(k) and Sp(k) is instructive and impor-
tant, both for use of the Dorfman procedure considered here and for when considering other testing strategies. The
analysis presented demonstrates clearly some of the potential pitfalls of pretending to know too much. In this analy-
sis, emphasis is on sampling directly from the population under study for the validation component in determining the
use or not of group testing in a particular application. While this ideal situation should be employed whenever practi-
cal, as the authors note in the Discussion, more economical alternatives might be considered based on the technology
underlying the assays or on population characteristics. To balance costs and evaluation, one might, for example, consider
hybrids or combinations of both direct population sampling and laboratory contrived samples with well-controlled prop-
erties, such as the target-spiked samples the authors mention. Evaluation of such would almost certainly be needed on a
case-by-case basis, but thorough consideration might be expected to lead to both improved testing efficiency and economic
gains.
As presented, costs are characterized using the total number of tests performed per individual and total numbers of
tests needed to warrant group testing. The authors do note that, “some authors include a cost for incorrect classification,”
but they then go to say that this “may be difficult to motivate from a medical or public health perspective.” Detailed eco-
nomic evaluation of interventions and screening tools are often encouraged (eg, References 1,2) to justify decisions and
recommendations in public health, especially in times of decreasing budgets and increasing burdens. While such analy-
ses can be difficult and intricate and would obviously require a great deal of detailed costing information, enlistment of
health economists to collaborate in such an evaluation should provide more refined, complete, and defensible analyses.
(Examples of readily available background information on economic analyses of this sort include the U.S. Department of
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Health and Human Services [aspe.hhs.gov/system/files/pdf/74686/report.pdf] the U.S. Centers for Disease Control and
Prevention [www.cdc.gov/policy/polaris/economics/cost-effectiveness.html] and the World Health Organization [www.
who.int/choice/publications/p_2003_generalised_cea.pdf].) The good news here, of course, is that while such extensive
analyses were not considered by the authors here, their demonstration of the need to correctly calculate group testing
performance and numbers of tests required, especially in the presence of differential misclassification, moves the nee-
dle toward more rigorous evaluation. Implementation of these recommendations should, therefore, directly and more
correctly inform more comprehensive economic analyses.
Finally, while the authors’ focus was on group testing for identification, some of the lessons learned also apply to
group testing for estimation. Correct specification of test performance parameters is essential in estimation applications
that account for imperfect tests, especially if values are treated as known and so uncertainty in these is not incorporated
into inferential statements. In applications involving estimation of virus prevalence in mosquito populations based on
samples of trapped mosquitoes, for example, test performance characteristics may be included in estimation based on
recent work3 applying Firth’s correction to effectively eliminate bias in estimation using imperfect tests and allowing for
group size-dependent sensitivities and specificities (ie, for differential misclassification). Consider a simple, realistic, but
contrived example with 20 groups (pools) each of sizes 10, 25, 50, 100, with 1, 0, 3, 5 of these groups positive, respectively.
The percent difference in estimates of the population proportion positive based on this varied more than 8%, from 2.8 to 3.1
per 1000, when group-specific sensitivies were changed from (1.0, 0.975, 0.95, 0.9) to (1, 0.95, 0.9, 0.8). The difference using
the latter sensitivities was over 15% when compared with perfect testing. Though they may appear small, such differences
in estimates may impact governmental agency decisions regarding community interventions for mosquito abatement.
Laboratory work (eg, Reference 4) characterizing sensitivies and specificies of assays for mosquito testing by group size can
be used to inform such estimation. Another key recommendation of the authors that applies to estimation as well is to be
sure to define carefully the population to which test characteristics apply. In the estimation of virus infection prevalence in
mosquitoes, careful attribution of testing characteristics to both virus and mosquito species would be essential for proper
implementation in estimation.
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